coin-img-ETHETH-0.75%coin-img-BTCBTC-1.83%coin-img-SOLSOL-0.46%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.85%coin-img-RAVERAVE-22.00%coin-img-TRXTRX-1.25%coin-img-HYPEHYPE-1.32%coin-img-ETHETH-0.75%coin-img-BTCBTC-1.83%coin-img-SOLSOL-0.46%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.85%coin-img-RAVERAVE-22.00%coin-img-TRXTRX-1.25%coin-img-HYPEHYPE-1.32%coin-img-ETHETH-0.75%coin-img-BTCBTC-1.83%coin-img-SOLSOL-0.46%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.85%coin-img-RAVERAVE-22.00%coin-img-TRXTRX-1.25%coin-img-HYPEHYPE-1.32%coin-img-ETHETH-0.75%coin-img-BTCBTC-1.83%coin-img-SOLSOL-0.46%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.85%coin-img-RAVERAVE-22.00%coin-img-TRXTRX-1.25%coin-img-HYPEHYPE-1.32%
user-avatar
CBS News

Medicare to launch GLP-1 weight-loss drug coverage pilot on July 1, 2026 with $50 monthly copay

AI Market Summary
CMS will launch an 18-month "Medicare GLP-1 Bridge" pilot starting July 1, 2026, allowing eligible Part D beneficiaries to access obesity-only GLP-1 therapies with a $50 monthly copay. The program expands reimbursed demand for Eli Lilly's Zepbound/Foundayo and Novo Nordisk's Wegovy, potentially improving near-term volume visibility, while the 2027 end date and lack of a defined extension path create policy-duration uncertainty.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT-2.24%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The Centers for Medicare & Medicaid Services will begin an 18-month pilot program on July 1, 2026 to cover GLP-1 drugs prescribed for weight loss, including Eli Lilly’s (LLY) Zepbound and Foundayo and Novo Nordisk’s (NVO) Wegovy. Eligible Medicare beneficiaries will pay a $50 monthly copay and will not need to meet the Part D deductible. The program is expected to cover about 3.8 million patients and is scheduled to expire at the end of 2027, leaving future coverage uncertain.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.